What amount sold does Pharmaceutics International, Inc. report in Form D filings?

The latest linked filings report $196.5M sold across 16 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Pharmaceutics International, Inc.'s most recent SEC filing?

Pharmaceutics International, Inc.'s most recent Form D filing was on 2024-10-23.

How many investors does Pharmaceutics International, Inc. have?

The most recent Form D filing lists 3 investor(s).

What type of securities does Pharmaceutics International, Inc. offer?

Pharmaceutics International, Inc.'s SEC Form D filings indicate equity offerings.

Pharmaceutics International, Inc.

CIK: 0001684470·Pharmaceuticals·HUNT VALLEY, MD·Corporation

Reported Sold

$196,479,897

Total Filings

Identified Offerings

Last Filed

Oct 23, 2024

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

Oct 23, 2024Form D/A — Amendment

Reported sold: $11,249,998 · Target: $11,249,998

Rule 506(b)·3 investors

Changed: Reported amount sold, Offering target

Jun 11, 2024Form D — New notice

Reported sold: $4,249,990 · Target: $8,249,990

Rule 506(b)·3 investors

Mar 13, 2024Form D — New notice

Reported sold: $4,249,989 · Target: $4,249,989

Rule 506(b)·6 investors

Jun 27, 2023Form D — New notice

Reported sold: $6,000,000 · Target: $12,000,000

Rule 506(b)·2 investors

Dec 12, 2022Form D — New notice

Reported sold: $3,000,159 · Target: $3,000,159

Rule 506(b)·5 investors

Oct 7, 2022Form D — New notice

Reported sold: $9,007,812 · Target: $9,007,812

Rule 506(b)·5 investors

Aug 22, 2022Form D — New notice

Reported sold: $5,000,319 · Target: $5,000,319

Rule 506(b)·5 investors

Jul 12, 2022Form D — New notice

Reported sold: $5,000,319 · Target: $5,000,319

Rule 506(b)·5 investors

May 5, 2022Form D — New notice

Reported sold: $5,000,000 · Target: $5,000,000

Rule 506(b)·4 investors

Mar 17, 2022Form D — New notice

Reported sold: $5,000,319 · Target: $5,000,319

Rule 506(b)·4 investors

Jan 11, 2022Form D — New notice

Reported sold: $5,000,159 · Target: $5,000,159

Rule 506(b)·2 investors

Oct 29, 2021Form D — New notice

Reported sold: $5,000,159 · Target: $5,000,159

Rule 506(b)·2 investors

Aug 6, 2021Form D — New notice

Reported sold: $6,000,000 · Target: $6,000,000

Rule 506(b)·5 investors

Jun 4, 2021Form D — New notice

Reported sold: $3,000,159 · Target: $3,000,159

Rule 506(b)·4 investors

Jun 4, 2021Form D — New notice

Reported sold: $10,000,000 · Target: $10,000,000

Rule 506(b)·6 investors

Oct 29, 2018Form D — New notice

Reported sold: $5,971,142 · Target: $15,000,000

Rule 506(b)·5 investors

Sep 14, 2016Form D — New notice

Reported sold: $107,999,363 · Target: $107,999,363

Rule 506(b)·9 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 16 identified offerings

$196,479,897

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Michael Bogda

Related Person

Appears on 16 filings

David Solomon

Related Person

Appears on 14 filings

Syed E. Abidi, Ph.D.

Related Person

Appears on 12 filings

John Guthrie

Related Person

Appears on 9 filings

John Fowler

Related Person

Appears on 8 filings

James Gale

Related Person

Appears on 7 filings

James E. Gale

Related Person

Appears on 6 filings

Sana I. Abidi

Related Person

Appears on 6 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Oct 23, 2024	Amendment	$11,249,998	$11,249,998	3
Jun 11, 2024	New	$8,249,990	$4,249,990	3
Mar 13, 2024	New	$4,249,989	$4,249,989	6
Jun 27, 2023	New	$12,000,000	$6,000,000	2
Dec 12, 2022	New	$3,000,159	$3,000,159	5
Oct 7, 2022	New	$9,007,812	$9,007,812	5
Aug 22, 2022	New	$5,000,319	$5,000,319	5
Jul 12, 2022	New	$5,000,319	$5,000,319	5
May 5, 2022	New	$5,000,000	$5,000,000	4
Mar 17, 2022	New	$5,000,319	$5,000,319	4
Jan 11, 2022	New	$5,000,159	$5,000,159	2
Oct 29, 2021	New	$5,000,159	$5,000,159	2
Aug 6, 2021	New	$6,000,000	$6,000,000	5
Jun 4, 2021	New	$10,000,000	$10,000,000	6
Jun 4, 2021	New	$3,000,159	$3,000,159	4
Oct 29, 2018	New	$15,000,000	$5,971,142	5
Sep 14, 2016	New	$107,999,363	$107,999,363	9

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Pierrepont Therapeutics, Inc.

Pharmaceuticals

Offering target: $5,859,876

Filed Sep 22, 2026